EGA
CBAY

Eagle Global Advisors’s Cymabay Therapeutics CBAY Stock Holding History

Eagle Global Advisors’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-16,630
Closed -$115K – 403
2015
Q1 		$115K Buy
+16,630
New +$160K ﹤0.01% 339

Other funds holding CBAY

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IHM
Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Eagle Global Advisors's CBAY Position: Q2 2015 in Review

Eagle Global Advisors sold out of Cymabay Therapeutics (CBAY) in Q2 2015, closing a stake of 16,630 shares — an estimated $115K sold.

Eagle Global Advisors first reported a position in CBAY in Q1 2015 and held it in 1 quarter. The position peaked at $115K in Q1 2015. 29 funds tracked by Wall St. Rank hold CBAY as of Q2 2015.

  • Eagle Global Advisors reported no remaining Cymabay Therapeutics position as of Q2 2015 after selling out during the quarter.
  • Eagle Global Advisors sold 16,630 Cymabay Therapeutics shares in Q2 2015, an estimated $115K.
  • Eagle Global Advisors first reported a position in Cymabay Therapeutics in Q1 2015 and held it in 1 quarter.
  • Eagle Global Advisors's Cymabay Therapeutics position peaked at $115K in Q1 2015.
  • 29 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2015.

Based on Eagle Global Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.